Lessee, Operating Lease, Liability, to be Paid, Year One of ABVC BIOPHARMA, INC. from 30 Jun 2023 to 31 Dec 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).
Summary
ABVC BIOPHARMA, INC. quarterly Lessee, Operating Lease, Liability, to be Paid, Year One in USD history and change rate from 30 Jun 2023 to 31 Dec 2025.
  • ABVC BIOPHARMA, INC. Lessee, Operating Lease, Liability, to be Paid, Year One for the quarter ending 31 Dec 2025 was $441,029, a 7.7% increase year-over-year.
Source SEC data
View on sec.gov
Lessee, Operating Lease, Liability, to be Paid, Year One, Quarterly (USD)
Lessee, Operating Lease, Liability, to be Paid, Year One, YoY Quarterly Change (%)

ABVC BIOPHARMA, INC. Quarterly Lessee, Operating Lease, Liability, to be Paid, Year One (USD)

Period Value YoY Chg Change % Date Report Filed Fiscal Year Fiscal Period
Q4 2025 $441,029 +$31,442 +7.7% 31 Dec 2025 10-K 03 Mar 2026 2025 FY
Q3 2025 $118,597 -$231,491 -66% 30 Sep 2025 10-Q/A 03 Mar 2026 2025 Q3
Q2 2025 $111,218 -$239,397 -68% 30 Jun 2025 10-Q 13 Aug 2025 2025 Q2
Q1 2025 $104,849 -$245,960 -70% 31 Mar 2025 10-Q 30 Apr 2025 2025 Q1
Q4 2024 $409,587 +$4,842 +1.2% 31 Dec 2024 10-K 15 Apr 2025 2024 FY
Q3 2024 $350,088 +$253,503 +262% 30 Sep 2024 10-Q 14 Nov 2024 2024 Q3
Q2 2024 $350,615 +$156,048 +80% 30 Jun 2024 10-Q 14 Aug 2024 2024 Q2
Q1 2024 $350,809 31 Mar 2024 10-Q 17 May 2024 2024 Q1
Q4 2023 $404,745 31 Dec 2023 10-K 13 Mar 2024 2023 FY
Q3 2023 $96,585 30 Sep 2023 10-Q 15 Nov 2023 2023 Q3
Q2 2023 $194,567 30 Jun 2023 10-Q 14 Aug 2023 2023 Q2
* An asterisk sign (*) next to the value indicates that the value is likely invalid.